Xiukun Hou
Department Of Thyroid And Neck Tumor
Tianjin, China
Tianjin, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
PRDM16 Drives Thyroid Cancer Differentiation via a TRIM58-MVP Axis to Suppress MAPK and PI3K/AKT Signaling.
Journal: International journal of biological sciences
Published: January 08, 2026
Enhancer-mediated NR2F2 recruitment activates BGN to promote tumor growth and shape tumor microenvironment in papillary thyroid cancer.
Journal: Theranostics
Published: March 13, 2025
Identification of stemness subtypes and prognostic modeling in thyroid cancer: the critical role of DPYSL3 in tumor progression and immune microenvironment.
Journal: Discover oncology
Published: March 05, 2025
Enhancer hijacking drives FAM20C expression to promote papillary thyroid cancer progression.
Journal: Cancer gene therapy
Published: January 24, 2025
Multifocality increases the risk of central compartment lymph node metastasis but is not related to the risk of recurrence and death in papillary thyroid carcinoma.
Journal: Gland surgery
Published: November 22, 2024
NSUN2-mediated m5C modification drives alternative splicing reprogramming and promotes multidrug resistance in anaplastic thyroid cancer through the NSUN2/SRSF6/UAP1 signaling axis.
Journal: Theranostics
Published: October 05, 2024
DDX18 coordinates nucleolus phase separation and nuclear organization to control the pluripotency of human embryonic stem cells.
Journal: Nature communications
Published: August 14, 2024
Predictive and prognostic value of aurora kinase A combined with tumor-infiltrating lymphocytes in medullary thyroid carcinoma.
Journal: Frontiers in oncology
Published: January 31, 2024
An Inducible CRISPR-dCas9-Based Transcriptional Repression System for Cancer Therapy.
Journal: Small methods
Published: September 26, 2023
ABCB11 accumulated in immature tertiary lymphoid structures participates in xenobiotic metabolic process and predicts resistance to PD-1/PD-L1 inhibitors in head and neck squamous cell carcinoma.
Journal: Translational oncology
Published: May 04, 2023
METTL3 inhibition induced by M2 macrophage-derived extracellular vesicles drives anti-PD-1 therapy resistance via M6A-CD70-mediated immune suppression in thyroid cancer.
Journal: Cell death and differentiation
Published: January 31, 2023
PARP inhibitor shuts down the global translation of thyroid cancer through promoting Pol II binding to DIMT1 pause.
Journal: International journal of biological sciences
Published: December 15, 2022
Last Updated: 09/26/2026